Bailard, Inc. Fibrogen Inc Transaction History

Bailard, Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 13, 2021	SELL	$18.57 - $35.68 $120,946 - $232,383	-6,513 Closed	0 $0
Q1 2021 May 13, 2021	SELL	$31.0 - $55.72 $189,100 - $339,892	-6,100 Reduced 48.36%	6,513 $226,000
Q4 2020 Feb 03, 2021	SELL	$37.09 - $48.97 $130,927 - $172,864	-3,530 Reduced 21.87%	12,613 $468,000
Q3 2020 Nov 10, 2020	BUY	$40.47 - $45.5 $121,410 - $136,500	3,000 Added 22.83%	16,143 $664,000
Q1 2020 Apr 16, 2020	BUY	$23.3 - $45.96 $69,900 - $137,880	3,000 Added 29.58%	13,143 $457,000
Q4 2019 Jan 31, 2020	BUY	$34.58 - $48.06 $39,524 - $54,932	1,143 Added 12.7%	10,143 $435,000
Q3 2019 Oct 18, 2019	SELL	$36.98 - $48.45 $184,899 - $242,250	-5,000 Reduced 35.71%	9,000 $333,000
Q2 2019 Jul 26, 2019	BUY	$35.13 - $55.53 $210,780 - $333,180	6,000 Added 75.0%	14,000 $633,000
Q2 2018 Aug 08, 2018	SELL	$44.9 - $64.95 $89,800 - $129,900	-2,000 Reduced 20.0%	8,000 $501,000
Q1 2018 May 07, 2018	SELL	$45.35 - $61.65 $90,700 - $123,300	-2,000 Reduced 16.67%	10,000 $462,000
Q4 2017 Feb 08, 2018	BUY	$41.95 - $60.1 $503,400 - $721,200	12,000	12,000 $0

47.1M

387K

672K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $32.8M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of Bailard, Inc., based on Form 13F filings with the SEC.

Stay updated on Bailard, Inc. with notifications on news.